Elisabet Gimbringer
Corporate Officer/Principal bij KAROLINSKA DEVELOPMENT AB
Oorsprong van het eerstegraads netwerk van Elisabet Gimbringer
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Financial Conglomerates | 30 | |
KD Incentive AB
3
| Subsidiary | 3 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Elisabet Gimbringer via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| AEROCRINE AB | Electronic Equipment/Instruments | Founder | |
| TIANJIN BINHAI TEDA LOGISTICS (GROUP) CORPORATION LIMITED | Air Freight/Couriers | Director/Board Member Director/Board Member | |
Vattenfall AB
 Vattenfall AB Electric UtilitiesUtilities Vattenfall AB engages in the generation, distribution, and sale of heat and electricity. It operates through the following segments: Heat, Customers and Solutions, Wind, Power Generation, and Distribution. The company was founded in 1909 and is headquartered in Solna, Sweden. | Electric Utilities | Director/Board Member General Counsel | |
| MEDIVIR AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| SINO BIOPHARMACEUTICAL LIMITED | Pharmaceuticals: Major | Founder Corporate Officer/Principal Chairman Corporate Officer/Principal | |
| Karolinska Institutet | College/University | Chairman Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
Karolinska Institutet Holding AB
 Karolinska Institutet Holding AB Investment Trusts/Mutual FundsMiscellaneous Part of Karolinska Institutet Holding AB, Nätverk Karolinska Institutet Science Park AB (KISP) facilitates interaction between academia and industry on Campus Solna. The company is based in Solna, Sweden. KISP collaborates closely with Karolinska Institutet, Akademiska Hus, and AWL to organize seminars, workshops, and networking events that help researchers, startups, and established companies connect and gain new insights. The CEO of the Swedish company is Karl Johan Ingvar Weigelt. | Investment Trusts/Mutual Funds | Chief Executive Officer General Counsel | |
Beijing Tide Pharmaceutical Co., Ltd.
 Beijing Tide Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Tide Pharmaceutical Co., Ltd. engages in research, development, manufacturing and sale of pharmaceutical products. The firm's products include kaifen flurbiprofen axetil injection, kaishi alprostadil injection, kaina beraprost sodium tablet and deyou pronase granules. The company was founded in May 1995 and is headquartered in Beijing, China. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
SEB Venture Capital
 SEB Venture Capital Investment ManagersFinance SEB Venture Capital (SEB Venture Capital) is a venture capital subsidiary of Skandinaviska Enskilda Banken AB founded in 1995. The firm is headquartered in Stockholm, Sweden. | Investment Managers | Corporate Officer/Principal | |
| Chalmers University of Technology | College/University | Chairman Graduate Degree | |
| Stockholm School of Economics | College/University | Undergraduate Degree Masters Business Admin | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Chairman Chief Executive Officer Chief Executive Officer Director of Finance/CFO Chief Executive Officer Chief Executive Officer Director of Finance/CFO Director of Finance/CFO Private Equity Analyst | |
| ABLYNX | Biotechnology | Chairman Director/Board Member | |
| SCIBASE HOLDING AB (PUBL) | Medical Specialties | Director/Board Member Director/Board Member | |
| University of Lund | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Graduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree | |
| VIVESTO AB | Pharmaceuticals: Generic | Director of Finance/CFO Chairman | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Chief Administrative Officer | |
| DIUL GROUP | Pharmaceuticals: Major | Chairman | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| PROMIMIC AB | Medical Specialties | Director/Board Member Corporate Officer/Principal Director/Board Member | |
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member Director of Finance/CFO | |
| KCIF Fund Management AB | Director/Board Member Chairman Chairman Director/Board Member | ||
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The company was founded in 1969, and the CEO is Kang Xin Yu. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
Caerus Consulting AS
 Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member Director of Finance/CFO | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NovaSAID AB
 NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Comptroller/Controller/Auditor Chairman | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member Chairman | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Chairman Director/Board Member Director/Board Member | |
| OSSDSIGN AB | Medical Specialties | Director/Board Member Director/Board Member | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman Chief Executive Officer Director/Board Member | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Chairman Director/Board Member Chief Executive Officer | |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
| Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd. | Director/Board Member Director/Board Member | ||
| Scibase AB | Director/Board Member Director/Board Member | ||
Svenska Vaccinfabriken Produktion AB
 Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member | |
Softhale NV
 Softhale NV Miscellaneous Commercial ServicesCommercial Services Softhale NV engages in manufacturing medical, clinical and pharmaceutical equipment. The company was founded by Jurgen Rawert and Frank Bartels and is headquartered in Diepenbeek, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Perma Ventures AB
 Perma Ventures AB Investment ManagersFinance Perma Ventures AB provides financial advisory services. The private company is based in Stockholm, Sweden. | Investment Managers | Director/Board Member Director/Board Member | |
VOC Diagnostics AB
 VOC Diagnostics AB Medical/Nursing ServicesHealth Services VOC Diagnostics AB is a cancer diagnostics firm focusing on detection of ovarian cancer as a first indication. The company was founded by György Horvath in 2017 and is headquartered in Solna, Sweden. | Medical/Nursing Services | Chairman Chief Executive Officer | |
AnaCardio AB
 AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
invoX Pharma Ltd.
 invoX Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., invoX Pharma Ltd. is a British biopharmaceutical company. The company is based in Kingston-upon-Thames, UK. The company was founded in 2021. Benjamin Toogood has been the CEO of the company since 2023. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Chief Investment Officer | |
Sino Biopharmaceutical (Beijing) Ltd.
 Sino Biopharmaceutical (Beijing) Ltd. Miscellaneous Commercial ServicesCommercial Services Sino Biopharmaceutical (Beijing) Ltd. is an investment holding company. Its sole asset is its 33.6% interest in Beijing Tide Pharmaceutical Co., Ltd., a pharmaceutical company established in China with limited liability, which develops, manufactures, and market pharmaceutical products. Sino Biopharmaceutical (Beijing) was founded on December 31, 2007 and is headquartered in Hong Kong. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member |
Statistieken
Internationaal
| Zweden | 37 |
| China | 5 |
| Hongkong | 3 |
| België | 3 |
| Denemarken | 3 |
Sectoraal
| Health Technology | 26 |
| Commercial Services | 8 |
| Consumer Services | 6 |
| Finance | 4 |
| Electronic Technology | 2 |
Operationeel
| Director/Board Member | 300 |
| Chairman | 90 |
| Corporate Officer/Principal | 86 |
| Independent Dir/Board Member | 45 |
| Chief Executive Officer | 38 |
Sterkste connecties
| Insiders | |
|---|---|
| Gunnar Magnus Modee Persson | 51 |
| Ping Tse | 43 |
| Viktor Drvota | 41 |
| Bo Jesper Hansen | 34 |
| Per Gunnar Ernst Aniansson | 31 |
| Hans Lennart Rudolf Wigzell | 30 |
| Khalid Islam | 29 |
| Karl Härfstrand | 23 |
| Jim van Heusden | 22 |
| Carl Johan Bertil Sundberg | 21 |
| Henrijette Richter | 21 |
| Ewa Björling | 21 |
| Terje Kalland | 20 |
| Anna Lefevre Skjöldebrand | 17 |
| Björn Cochlovius | 15 |
- Beurs
- Insiders
- Elisabet Gimbringer
- Bedrijfsconnecties
